[PRESSWIRE] Asia - 03.05.22 -- In South Korea, in cooperation with Heavenly Culture, World Peace and Restoration of Light (HWPL), 18,000 members of Shincheonji Church of Jesus and HWPL participated in blood donation for two weeks from April 18th. This number was recorded as the largest group blood donation in the country.

[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

[PRESSWIRE] Austria - 10.12.21 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).

[PRESSWIRE] Japan - 21 October, 2021 -- Post COVID-19 syndrome, a developing world-wide problem may be alleviated by Japan originated medical device "suisonia".

[PRESSWIRE] Austria - 04 May, 2021 -- CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.

[PRESSWIRE] Vienna, Austria - 17 February, 2021 -- In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.

[PRESSWIRE] Austria - 19.11.20 -- Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company, today announces the publication of preclinical data with ShigETEC, its vaccine candidate against Shigellae and Enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines8040689).

[PRESSWIRE] Vienna - 30th June 2020 -- Eveliqure Biotechnologies today announces that further financing has been secured from Arax Capital Partners comprising the last instalment of a €1.7M total investment provided by Arax. This is complemented by further private investment from Baobá and a Swiss based family office, and totals around €0.5M.

[PRESSWIRE] Vienna - 4 June, 2020 -- The Austrian biotech company CEBINA GmbH announces that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale efforts offering short-, mid- and longer-term solutions to fight the COVID-19 pandemic. This seed funding will support proof-of-concept studies of the vaccine that will allow progress to pre-clinical development, scheduled for Q1/2021. The funds are provided by the Blom Family Office.

[PRESSWIRE] La Paz, Bolivia - 10 October, 2018 -- What may well be the world’s ugliest family of frogs is facing extinction before some of them even have a name for their species - due to a deadly fungus, climate change and pollution.